Human Milk Oligosaccharides Enhance Hippocampal Plasticity and Anti‑Inflammatory Microglia via the Gut‑Brain Immune Axis

The Finding

Zhou et al. (Gale and Ira Drukier Institute for Children’s Health) performed a narrative review and concluded that human milk oligosaccharides (HMOs) foster a beneficial gut microbiota, boost hippocampal plasticity, and steer microglia toward an anti‑inflammatory phenotype.

How They Got There

The authors surveyed peer‑reviewed studies spanning animal models, in vitro assays, and limited human observations. Primary outcomes extracted included:

• Relative abundance of Bifidobacterium and other saccharolytic taxa.


• Markers of hippocamp plasticity such as synaptic density and BDNF expression.


• Microglial polarization indices (e.g., IL‑4‑driven M2 markers versus pro‑inflammatory cytokines).


• Levels of short‑chain fatty acids (SCFAs), tryptophan metabolites, and secondary bile acids.

When three or more quantitative results were reported, the review summarized them in a comparative table:

The Mechanism: What Happens Biologically

HMOs escape host digestion and become substrates for specific gut microbes, especially Bifidobacterium spp. Fermentation yields SCFAs that activate G‑protein‑coupled receptors GPR41/43 on enteroendocrine cells and microglia, leading to histone deacetylase inhibition and up‑regulation of IL‑4‑responsive genes. Parallelly, microbial conversion of tryptophan produces indole derivatives that bind the aryl hydrocarbon receptor (AhR), dampening NF‑κB activity in microglia. Secondary bile acids engage the FXR/TGR5 axis, further curbing pro‑inflammatory cytokine release. The combined signaling cascade converges on the hippocampus, where elevated BDNF and synaptic protein expression support neurogenesis and synaptic pruning.

Study Limitations

• Reliance on preclinical models limits direct extrapolation to adult human physiology.


• Heterogeneity in HMO formulations across studies prevents a unified dose‑response analysis.


• Scarcity of longitudinal human trials leaves long‑term safety and efficacy largely uncharacterized.

Practical Application

Current evidence does not yet support a concrete supplementation protocol for healthy adults. To move from theory to practice, randomized controlled trials measuring gut microbiota shifts, hippocampal imaging outcomes, and microglial biomarkers after defined HMO doses are required. Until such data emerge, the finding remains a mechanistic insight rather than an actionable regimen.

Disclaimer: This article is for informational and educational purposes only. The information presented does not constitute medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before modifying your diet, supplementation, or exercise routines. The scientific studies cited reflect the state of knowledge at their publication date and may be subject to revision.